Skip to content
Report Presentation Webcast
December 14, 2022 A Look into Calliditas’ China Commercial Partner Everest Medicines
November, 2022 Corporate Presentation
November 14, 2022 Interim Report Q3 2022
November 8, 2022 KOL Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape
August 18, 2022 Interim Report Q2 2022
May 18, 2022 Interim Report Q1 2022
April 27, 2022 Annual report 2021
February 24, 2022 Year-end report 2021
December 16, 2021 FDA Approval – Investor Update
November 18, 2021 Interim Report Q3 2021
August 19, 2021 Interim Report Q2 2021
May 18, 2021 Interim Report Q1 2021
April 27, 2021 Annual Report 2020
March 10, 2021 KOL Perspectives: The Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice
February 18, 2021 Year-end report 2020
November 12, 2020 Interim Report Q3 2020
November 9, 2020 Conference call on positive topline results from pivotal phase 3 NefIgArd trial
August 13, 2020 Interim Report Q2 2020
May 14, 2020 Interim Report Q1 2020
April 28, 2020 Annual Report 2019
February 14, 2020 Year-end report 2019
November 14, 2019 Interim Report Q3 2019
August 15, 2019 Interim Report Q2 2019
May 8, 2019 Interim Report Q1 2019
April 4, 2019 Annual Report 2018
February 7, 2019 Year-end report 2018
November 1, 2018 Interim Report Q3 2018
August 16, 2018 Interim Report Q2 2018
April 24, 2018 Annual Report 2017, in Swedish
June 30, 2017 Annual Report 2016, in Swedish